Introduction: Primary mediastinal large B cell lymphoma (PMLBCL) represents a distinct clinicopathological entity of large B cell lymphoma occuring preferentially in young females with a bulky mediastinal mass. Methods: Between 1991 and April 2004, 92 consecutive untreated patients (pts) with PMLBCL were diagnosed and treated at our institution. The median age was 33 years (range 15–61), 68/92 (74%) were females,72 pts had stage II and 20 stage IIE, 43(47%) presented B symptoms, LDH was increased in 68(74%), 81(88%) had a bulky mass and 47(51%) had a superior vena cava syndrome. According to age-adjusted IPI score 52 pts had an IPI = 0–1 and 40 pts IPI = 2–3. All pts were treated with standard MACOP-B chemotherapy (CHT) and 86 pts underwent mediastinal radiation therapy (RT) at dose of 30–36 Gy. Six (7%) pts did not receive RT (refusal = 3, progression = 2, death = 1). The response was evaluated in all pts after CHT and at the end of RT. Results: After MACOP-B regimen the response rate was: CR/CRu = 72(78%), PR = 18 (20%), NR = 1(1%), toxic death = 1(1%). Six (6%) PR pts underwent to intensification therapy with high dose therapy and ASCT. After RT pts achieved CR/CRu = 78 (91%), PR = 3(3%), NR = 5(6%).After CHT 67 Gallium scan was positive in 51/60 (85%) while after RT was positive in 12/53(23%) P <0.0001.After a median follow-up of 58 months (1–165) relapse was observed in 9 pts. Five of the 9 relapsed pts are alive in CR after second line therapy with ASCT. Five not responding pts had progressive disease and died. To date 82 (90%) pts are currently in continuous CR. Projected 5-years OS and PFS are 88% and 84%, respectively. The 5 years OS was better for pts with IPI = 0–1 compared to IPI = 2–3 (96% vs 76% P = 0.006). Conclusions: Combined modality treatment using the MACOP-B regimen and mediastinal RT induces high response and survival rates. Radiation therapy plays an important role in the achievement of these results.

Primary mediastinal large B cell lymphoma with sclerosis: A clinical study of 92 patients treated at a single institution with macop-B and radiotherapy / Martelli, Maurizio; F., Natalino; DE SANCTIS, Vitaliana; E., Finolezzi; L., Bizzoni; M., Moleti; Pescarmona, Edoardo; L., Grapulin; Mandelli, Franco; Foa, Roberto. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 16 (SUPPL. 5):(2005), pp. 164-164. (Intervento presentato al convegno 9th International Conference on Malignant Lymphoma tenutosi a Lugano, SWITZERLAND nel JUN 09-11, 2005) [10.1093/annonc/mdi578].

Primary mediastinal large B cell lymphoma with sclerosis: A clinical study of 92 patients treated at a single institution with macop-B and radiotherapy

MARTELLI, Maurizio;DE SANCTIS, Vitaliana;PESCARMONA, Edoardo;MANDELLI, Franco;FOA, Roberto
2005

Abstract

Introduction: Primary mediastinal large B cell lymphoma (PMLBCL) represents a distinct clinicopathological entity of large B cell lymphoma occuring preferentially in young females with a bulky mediastinal mass. Methods: Between 1991 and April 2004, 92 consecutive untreated patients (pts) with PMLBCL were diagnosed and treated at our institution. The median age was 33 years (range 15–61), 68/92 (74%) were females,72 pts had stage II and 20 stage IIE, 43(47%) presented B symptoms, LDH was increased in 68(74%), 81(88%) had a bulky mass and 47(51%) had a superior vena cava syndrome. According to age-adjusted IPI score 52 pts had an IPI = 0–1 and 40 pts IPI = 2–3. All pts were treated with standard MACOP-B chemotherapy (CHT) and 86 pts underwent mediastinal radiation therapy (RT) at dose of 30–36 Gy. Six (7%) pts did not receive RT (refusal = 3, progression = 2, death = 1). The response was evaluated in all pts after CHT and at the end of RT. Results: After MACOP-B regimen the response rate was: CR/CRu = 72(78%), PR = 18 (20%), NR = 1(1%), toxic death = 1(1%). Six (6%) PR pts underwent to intensification therapy with high dose therapy and ASCT. After RT pts achieved CR/CRu = 78 (91%), PR = 3(3%), NR = 5(6%).After CHT 67 Gallium scan was positive in 51/60 (85%) while after RT was positive in 12/53(23%) P <0.0001.After a median follow-up of 58 months (1–165) relapse was observed in 9 pts. Five of the 9 relapsed pts are alive in CR after second line therapy with ASCT. Five not responding pts had progressive disease and died. To date 82 (90%) pts are currently in continuous CR. Projected 5-years OS and PFS are 88% and 84%, respectively. The 5 years OS was better for pts with IPI = 0–1 compared to IPI = 2–3 (96% vs 76% P = 0.006). Conclusions: Combined modality treatment using the MACOP-B regimen and mediastinal RT induces high response and survival rates. Radiation therapy plays an important role in the achievement of these results.
2005
9th International Conference on Malignant Lymphoma
04 Pubblicazione in atti di convegno::04d Abstract in atti di convegno
Primary mediastinal large B cell lymphoma with sclerosis: A clinical study of 92 patients treated at a single institution with macop-B and radiotherapy / Martelli, Maurizio; F., Natalino; DE SANCTIS, Vitaliana; E., Finolezzi; L., Bizzoni; M., Moleti; Pescarmona, Edoardo; L., Grapulin; Mandelli, Franco; Foa, Roberto. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 16 (SUPPL. 5):(2005), pp. 164-164. (Intervento presentato al convegno 9th International Conference on Malignant Lymphoma tenutosi a Lugano, SWITZERLAND nel JUN 09-11, 2005) [10.1093/annonc/mdi578].
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/485158
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact